Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polinevrin is a metabolic support product developed by Valenta Pharmaceuticals, primarily used for the management of peripheral neuropathies, including polyneuropathy. Although registered in Russia as a biologically active food additive (dietary supplement) rather than a traditional pharmaceutical drug, it is formulated to support the structural and functional recovery of the nervous system. The product contains uridine monophosphate, a key nucleotide that serves as a precursor for the synthesis of pyrimidine nucleotides and phospholipids required for the repair of neuronal membranes and myelin sheaths. By providing essential building blocks for nerve regeneration, Polinevrin aims to improve reflex reactions and alleviate symptoms associated with nerve damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Polinevrin.